WHEN SHOULD YOU CONSIDER
SANCUSO® (granisetron transdermal system)
Learn More ABOUT SANCUSO
Request FREE SAMPLES
ONLY Sancuso Keep Them Covered
CINV = chemotherapy-induced nausea and vomiting
THINK SANCUSO® FIRST
• SANCUSO® can help prevent chemotherapy-induced nausea and vomiting (CINV) in your appropriate patients
• SANCUSO® is the first and only prescription patch approved for the prevention of CINV and provides an alternative to taking pills to prevent nausea and vomiting caused by chemotherapy
• SANCUSO® Avoids the Peak-Trough Fluctuations in Blood Levels Seen with Daily Oral Granisetron2
• NCCN Guidelines include SANCUSO® as a preferred 5HT3 regimen4
• Patch Price Guarantee: At least 1 SANCUSO® patch per month for as little as $20 for commercially insured patients.
Please see Important Safety Information below
Learn More ABOUT SANCUSO
Request FREE SAMPLES
SANCUSO_Patch_Price_Guarantee
Important Safety Information
INDICATIONS AND USAGE
SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in adults receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days.
CONTRAINDICATIONS
SANCUSO® is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the transdermal system.
WARNINGS AND PRECAUTIONS
Progressive Ileus and Gastric Distention: SANCUSO® may mask a progressive ileus and/or gastric distention. This should be particularly considered before use of SANCUSO® in patients who have had recent abdominal surgery. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction.
Serotonin Syndrome: The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of SANCUSO® and other serotonergic drugs. If treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if SANCUSO® is used concomitantly with other serotonergic drugs.
Skin Reactions: In clinical trials with SANCUSO®, application site reactions were reported that were generally mild in intensity and did not lead to discontinuation of use. The incidence of reactions was comparable with placebo. If severe reactions, or a generalized skin reaction occur (e.g., allergic rash, including erythematous, macular, papular rash or pruritus), remove the SANCUSO® transdermal system.
Increased Drug Exposure with Use of External Heat Sources: Prolonged exposure to heat results in increasing plasma concentrations of granisetron during the period of heat exposure. Do not apply a heat pad or heat lamp over or in the vicinity of the SANCUSO® transdermal system and avoid extended exposure to heat.
Phototoxicity with Ultraviolet Light Exposure: Phototoxicity with Ultraviolet Light Exposure: Granisetron may be affected by direct natural or artificial sunlight, including sunlamps. An in vitro study using Chinese hamster ovary cells suggests that granisetron has the potential for photogenotoxicity. To avoid a potential skin reaction, advise patients to cover the application site of the transdermal system with clothing if there is a risk of exposure to direct natural or artificial sunlight throughout the period of wear and for 10 days following its removal.
ADVERSE REACTIONS
The most common adverse reaction (≥ 3%) is constipation.
You are encouraged to report suspected adverse reactions to Cumberland Pharmaceuticals, Inc. at 1-833-Sancuso or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing information
CINV = chemotherapy-induced nausea and vomiting
References:
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis. Version 2.2020.
2. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014;120:1453-1461.
3. Cawley MM, Benson LM. Current trends in managing oral mucositis. Clin J Oncol Nurs. 2005;9(5):584-592.
4. Di Lorenzo C, Youssef NN. Diagnosis and management of intestinal motility disorders. Semin Pediatr Surg. 2010;19:50-58.
5. Keller J, Layer P. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009;23:407-423.
6. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Head and Neck Cancer. Version 2.2020.
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer. Version 5.2020.
8. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-Small Cell Lung Cancer. Version 6.2020.
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric Cancer. Version 2.2020.
10. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Cervical Cancer. Version 1.2020.
11. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer. Version 1.2020.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Testicular Cancer. Version 3.2020.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Colon Cancer. Version 4.2020.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Rectal Cancer. Version 6.2020.
15. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8(2):187-198.
16. Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management, Cancer Manag Res. 2013;5:179-185.
17. NCCN Clinical Practice Guidelines in Oncology. Antiemesis.V 1.2023
www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed March 17, 2023
sancuso.com Request Samples Learn more about Patient Rx Solutions
CUMBERLAND
Note: This message was distributed from an e-mail account used for sending messages only. Please do not reply to this message.
© 2023 Cumberland Pharmaceuticals, Inc. Nashville, TN. All rights reserved.
PLT6500623

Unsubscribe.